Enzalutamide Treatment in COVID-19

  • STATUS
    Recruiting
  • participants needed
    500
  • sponsor
    Andreas Josefsson
Updated on 19 February 2024
covid-19
enzalutamide
oral contraceptives

Summary

COVID-19 is a disease with high rate of morbidity if symptomatic. There is a great need of treatments to decrease the severity. The vast majority of patients needing intensive care are men, and this may be due to the androgens, either by regulation of TMPRSS2, necessary for virus internalization, or other mechanisms. Enzalutamide is an antiandrogen inhibiting the expression of androgen regulated proteins, such as TMPRSS2. The aim of this trial is to evaluate a possible beneficial effect of short-term enzalutamide treatment of COVID-19 patients.

Details
Condition Corona Virus Infection, Covid 19
Age 50-100 years
Treatment Enzalutamide Pill
Clinical Study IdentifierNCT04475601
SponsorAndreas Josefsson
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Positive COVID-19 test
Mild to severe symptoms of COVID-19
Hospitalization
WHO performance status 0-3
Age above or equal to 50 years
Can understand all the requirements of the study, provide informed consent, and provide authorization of use and disclosure of personal health information
Estimated expected survival of 1 year (excluding symptoms due to COVID-19)

Exclusion Criteria

Severe allergy to Enzalutamide
Pregnant or breast-feeding women
Need of immediate mechanical ventilation
Current medication includes enzalutamide treatment
Stroke or Transitory Ischemic attack in medical history
Treatment for HIV
Treatment with tamoxifen
Treatment with immunosuppressive agents
Severe immunosuppressive disease
Treatment with warfarin or NOAC (Non-vitamin K-antagonist anticoagulants)
Previous seizure in medical history
Other serious illness or medical condition
Unstable cardiovascular disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.